Publication dates

All regions

Lymphoma Industry, September 2014 Market Reports from Top Publishers

You might be interested in: cancer, flow cytometry, hematology, more »


 
1-20 of about 8 900 reports for Lymphoma

Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

  • $ 4 995
  • Industry report
  • September 2014
  • by GBI Research

... Epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to non-hodgkin lymphoma (nhl ...

Burkitt Lymphoma - Pipeline Review, H2 2014

Burkitt Lymphoma - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • September 2014
  • by Global Markets Direct

... A snapshot of the global therapeutic landscape of burkitt lymphoma- the report reviews key pipeline products under drug profile section which includes, product description, moa and r&d brief, licensing ...

Future Horizons and Growth Strategies in the European Tumor Marker Testing Market 2014: Supplier Shares and Country Forecasts

Future Horizons and Growth Strategies in the European Tumor Marker Testing Market 2014: Supplier Shares and Country Forecasts

  • $ 12 800
  • Industry report
  • August 2014
  • by Venture Planning Group

... Analysis a. Chronic myelogenous leukemia (cml) b. Acute myeloid leukemia (aml) c. Acute lymphoblastic leukemia (all) d. Malignant lymphomas lymphoid malignancies e. Chronic lymphocytic ...

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

  • $ 7 995
  • Industry report
  • August 2014
  • by Global Data

... Opportunityanalyzer: non-hodgkin's b-cell lymphoma - opportunity analysis and forecast to 2018 opportunityanalyzer: non-hodgkin's b-cell lymphoma - opportunity analysis and forecast to 2018 ...

The Leukemia & Lymphoma Society, Inc. - Strategic SWOT Analysis Review

The Leukemia & Lymphoma Society, Inc. - Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • August 2014
  • by Global Data

... Or business research. - Key elements such as swot analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs. The leukemia & lymphoma society, inc ...

Vivia Biotech, S.L. - Product Pipeline Analysis, 2014 Update

Vivia Biotech, S.L. - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • August 2014
  • by Global Data

... Of drugs on patients blood samples. It offers exvitec technology platform, which is used in hematologic cancer research. Vivia provides treatments for hematological cancers, such as leukemia, lymphoma ...

Global Hodgkins Lymphoma Therapeutics Market 2014-2018

Global Hodgkins Lymphoma Therapeutics Market 2014-2018

  • $ 2 500
  • Industry report
  • August 2014
  • by Infiniti Research Limited

... Global hodgkins lymphoma therapeutics market 2014-2018 about hodgkin's lymphomahodgkin's lymphoma (hl) is defined as the cancer of the lymph tissue, which is part of our immune system. The exact ...

Trends in Therapeutic Partnering

Trends in Therapeutic Partnering

  • $ 3 995
  • Industry report
  • August 2014
  • by Currentpartnering

... Ovarian cancer partnering in numberstop ovarian cancer partnering deals by valuemost active ovarian cancer partnering companies24. lymphomalymphoma partnering in numberstop lymphoma partnering ...

Lymphoma Partnering 2009-2014

Lymphoma Partnering 2009-2014

  • $ 995
  • Industry report
  • August 2014
  • by Currentpartnering

... Links to online copies of actual lymphoma deals and contract documents as submitted to the securities exchange commission by companies and their partners, where available. Contract documents provide ...

 Anaplastic Large Cell Lymphoma (ALCL)-Pipeline Insights, 2014

Anaplastic Large Cell Lymphoma (ALCL)-Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • August 2014
  • by Delve Insight

... Insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under anaplastic large cell lymphoma (alcl ...

About 2 100 reports for Lymphoma

Download Unlimited Documents from Trusted Public Sources

Pathology Description in Europe

  • Diagnostic Utility of a Clonality Test for Lymphoproliferative D...
  • January 2013
    8 pages
  • Cancer  

  • Europe  

    United States  

    Taiwan  

View report >

14 Companies for Lymphoma

Read our Company Profiles

Novartis Inc.

Switzerland

Celgene Corp.

United States

GlaxoSmithKline P.L.C.

United States

Seattle Genetics Inc.

United States

Bristol-Myers Squibb Co.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.